Applied Genetic Technologies Corporation (AGTC) & Its Competitors Head to Head Survey

Applied Genetic Technologies Corporation (NASDAQ: AGTC) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Applied Genetic Technologies Corporation to similar businesses based on the strength of its risk, institutional ownership, profitability, dividends, earnings, analyst recommendations and valuation.

Volatility & Risk

Applied Genetic Technologies Corporation has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies Corporation’s peers have a beta of 6.66, indicating that their average stock price is 566% more volatile than the S&P 500.

Earnings & Valuation

This table compares Applied Genetic Technologies Corporation and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Applied Genetic Technologies Corporation $39.47 million $2.81 million 47.51
Applied Genetic Technologies Corporation Competitors $260.16 million $66.28 million -6.26

Applied Genetic Technologies Corporation’s peers have higher revenue and earnings than Applied Genetic Technologies Corporation. Applied Genetic Technologies Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Applied Genetic Technologies Corporation and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Genetic Technologies Corporation 0 1 6 0 2.86
Applied Genetic Technologies Corporation Competitors 765 3038 11198 227 2.71

Applied Genetic Technologies Corporation currently has a consensus price target of $11.71, suggesting a potential upside of 208.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.17%. Given Applied Genetic Technologies Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Applied Genetic Technologies Corporation is more favorable than its peers.

Insider and Institutional Ownership

54.6% of Applied Genetic Technologies Corporation shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.6% of Applied Genetic Technologies Corporation shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Applied Genetic Technologies Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Applied Genetic Technologies Corporation 4.28% 1.45% 1.05%
Applied Genetic Technologies Corporation Competitors -5,488.34% -451.42% -42.55%

Summary

Applied Genetic Technologies Corporation beats its peers on 8 of the 13 factors compared.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply